1. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
   Nina Rosa Neuendorff et al, 2016, Ann Hematol CrossRef
2. Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
   Theodora S Ross et al, 2014, Molecular & Cellular Oncology CrossRef
3. Atypical chronic myeloid leukemia in a German Shepherd Dog
   Christina L. Marino et al, 2017, J VET Diagn Invest CrossRef
4. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
   Simona Soverini et al, 2018, Mol Cancer CrossRef
5. Genetic Studies in the Evaluation of Myeloproliferative Neoplasms
   Gabriel C. Caponetti et al, 2018, Seminars in Hematology CrossRef
6. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
   Marte Karen Brattås et al, 2018, Biomark Res CrossRef
7. Potential Leukemic Cells Engraftment After Hematopoietic Stem Cell Transplantation From Unrelated Donors With Undiagnosed Chronic Leukemia
   M.P. Kawa et al, 2018, Transplantation Proceedings CrossRef
8. Low-Level BCR-ABL1 transcripts in Individuals without Overt Hematologic Malignancy
   Rebecca J. Leeman-Neill et al, 2019, Leukemia Research CrossRef
9. Characterization and targeting of neoplastic stem cells in Ph+chronic myeloid leukemia
   Michel Arock et al, 2015, Int. J. Hematol. Oncol. CrossRef
10. The Conundrum of Genetic “Drivers” in Benign Conditions
    Shumei Kato et al, 2016, JNCI J Natl Cancer Inst CrossRef
11. Gene fusions and chimeric RNAs, and their implications in cancer
    Hao Wu et al, 2019, Genes & Diseases CrossRef
12. The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
    Naranie Shanmuganathan et al, 2019, Curr Hematol Malig Rep CrossRef
13. Low prevalence of the BCR–ABL1 fusion gene in a normal population in southern Sarawak
    Jew Win Kuan et al, 2019, Int J Hematol CrossRef
14. CRISPR-engineered T cells in patients with refractory cancer
    Edward A. Stadtmauer et al, 2020, Science CrossRef
15. Chronic Myeloproliferative Neoplasms (Other Than Chronic Myeloid Leukemia)
    Matthew E. Keeney et al, 2020 CrossRef
16. BCR: a promiscuous fusion partner in hematopoietic disorders
    Malalage N. Peiris et al, 2019, Oncotarget CrossRef
17. Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia
    Laurie Freire Boullosa et al, 2018, Oncotarget CrossRef
18. Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome
    Grzegorz K. Przybylski et al, 2017, Oncotarget CrossRef
19. Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities
    Fabrizio Tabbò et al, 2016, Oncotarget CrossRef
20. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors
    Michele Baccarani et al, 2021, Leukemia CrossRef
21. Reverting to single-cell biology: The predictions of the atavism theory of cancer
    Kimberly J. Bussey et al, 2021, Progress in Biophysics and Molecular Biology CrossRef
22. The Biology and Pathogenesis of Chronic Myeloid Leukaemia
    Naranie Shanmuganathan et al, 2021 CrossRef
23. Systematic Review of Normal Subjects Harbouring BCR-ABL1 Fusion Gene
    Jew Win Kuan et al, 2020, Acta Haematol CrossRef
24. Acute Megakaryoblastic Leukemia Harboring a Subclone Expressing BCR-ABL1 Fusion Gene Product
    Emiko Kashima et al, 2021, Intern. Med. CrossRef
25. Unexpected suppression of tumorigenesis by c-MYC via TFAP4-dependent restriction of stemness in B lymphocytes
    Elena Tonc et al, 2021 CrossRef
26. One-Step Multiplexed Droplet Digital Polymerase Chain Reaction for Quantification of p190 BCR-ABL1 Fusion Transcript in B-Lymphoblastic Leukemia
    Ryan J. Martinez et al, 2022 CrossRef
27. Mantle Cell Lymphoma and the Evidence of an Immature Lymphoid Component
    Simone Valentin Hansen et al, 2022, Leukemia Research CrossRef
28. Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia
    Dawne N. Shelton et al, 2022, PLoS ONE CrossRef
29. Initial Clinical Characteristics of Acute Lymphoblastic Leukemia in Children and Their Relationship with the Efficacy of Induced Remission Therapy
    晓莲 徐, 2022, ACM CrossRef
30. Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia
    Mohammad Houshmand et al, 2022, Cell Death Dis CrossRef
31. JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander?
    Francesco Tarantini et al, 2022, Hematology CrossRef
32. Spatial-Temporal Genome Regulation in Stress-Response and Cell-Fate Change
    Jekaterina Erenpreisa et al, 2023, IJMS CrossRef
33. Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
    Ikhwan Rinaldi et al, 2023, JBM CrossRef
34. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
    Lara Boucher et al, 2023, IJMS CrossRef
35. Effects of low-dose ionizing radiation on genomic instability in interventional radiology workers
    Dominika Kochanova et al, 2023, Sci Rep CrossRef
36. STUDYING THE AGE OF ONSET AND DETECTION OF CHRONIC MYELOID LEUKEMIA USING A THREE-STAGE STOCHASTIC MODEL
    SURYADEEPTO NAG et al, 2024, J. Biol. Syst. CrossRef
37. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia
    Tamer Othman et al, 2024, American J Hematol CrossRef
38. Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population
    Jew Win Kuan et al, 2024, BMC Cancer CrossRef
39. Low‐Level BCR::ABL1 Transcript at Diagnosis in Childhood Leukemia: A 10‐Year Single Institution Study
    Lucy E. Cain et al, 2024, Genes Chromosomes & Cancer CrossRef